A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphomaAn update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphomaGenome-wide association study identifies multiple risk loci for chronic lymphocytic leukemiaGenome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphomaIfosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphomaInternational Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).Lymphoid malignancies: a decade and a half of dramatic improvements in outcomeNCCN task force report: molecular markers in leukemias and lymphomasOptimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.Overview of lymphoma diagnosis and management.Treatment of follicular lymphoma: current statusTreatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report
author
alternateName
A Zelenetz AD Zelenetz, Andrew Zelenetz
@en
Andrew Zelenetz
@en
gender
type
comment
hulumtues
@sq
ikertzailea
@eu
researcher
@en
wetenschapper
@nl
дослідник
@uk
изилдөөчү
@ky
հետազոտող
@hy
গবেষক
@bn
ഗവേഷകൻ
@ml
研究者
@ja
label
Andrew D Zelenetz
@ast
Andrew D Zelenetz
@en
Andrew D Zelenetz
@es
Andrew D Zelenetz
@nl
Andrew D Zelenetz
@sl